BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The National Drug Abuse Treatment Clinical Trials Network - Northeast Node - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:The National Drug Abuse Treatment Clinical Trials Network - Northeast Node
X-ORIGINAL-URL:https://www.ctnnortheastnode.org
X-WR-CALDESC:Events for The National Drug Abuse Treatment Clinical Trials Network - Northeast Node
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20150308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20151101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20160313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20161106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20170312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20171105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20180311T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20181104T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220929T103000
DTEND;TZID=America/New_York:20220929T163000
DTSTAMP:20260525T062316
CREATED:20220908T010803Z
LAST-MODIFIED:20220908T010920Z
UID:3040-1664447400-1664469000@www.ctnnortheastnode.org
SUMMARY:Target Trial Emulation in Observational Research and Translational Testing of Advanced Digital Health Tools for SUD Prevention and Treatment
DESCRIPTION:REGISTER HERE! \nDescription: \nThis workshop aims to introduce these trending approaches; assess their strengths\, limitations\, and potential; discuss feasible research questions; identify study priorities\, and explore actionable strategies to address barriers and challenges for advancing substance use disorder (SUD) research. \nMeeting Chair: Lisa Marsch\, Ph.D. – Dartmouth College \nThe workshop consists of three subthemes with the following speakers:\nLearning Real-World Evidence of SUD from Nationwide Data Sources\nChristopher Jones\, Pharm.D.\, Dr.PH.\, M.P.H. – Centers for Disease Control and Prevention\nBeth Han\, M.D.\, Ph.D.\, M.P.H. – National Institute on Drug Abuse\, National Institutes of Health\nJulie Donohue\, Ph.D. – University of Pittsburgh \nTarget Trial Emulation in Observational Research\nSara Lodi\, Ph.D. – Boston University\nRolf Groenwold\, Ph.D. – Leiden University\, Netherlands\nJoshua Wallach\, Ph.D. M.S. – Yale University\nMarc LaRochelle\, M.D.\, M.P.H. – Boston University \nTranslational Testing of Clinical- and Community-Based Digital Health Systems\nBrandon Marshall\, Ph.D. – Brown University\nRebecca Rossom\, M.D.\, M.S. – HealthPartners\nJenny Lo-Ciganic\, Ph.D.\, M.S.Pharm. – University of Florida\nWalid Gellad\, M.D.\, M.P.H. – University of Pittsburgh\nMajid Afshar\, M.D.\, MSCR – University of Wisconsin-Madison \nOnce registered\, you will receive the Zoom information\, including an option to download a calendar invitation. If you have any questions about the meeting logistics\, please contact CTNSupport@leedmci.com. If you have any questions about this event\, please contact Dr. Xiaoming Wang at xiaoming.wang@nih.gov. \nIndividuals with disabilities who need sign language interpreting and/or other reasonable accommodations to participate in this event should contact Sean Randol at (240) 863-0507 or srandol@leedmci.com or through the Federal Relay (1-800-877-8339). Requests should be made at least five business days in advance of the event.
URL:https://www.ctnnortheastnode.org/event/target-trial-emulation-in-observational-research-and-translational-testing-of-advanced-digital-health-tools-for-sud-prevention-and-treatment/
CATEGORIES:Clinical Trials Network
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220929T103000
DTEND;TZID=America/New_York:20220929T163000
DTSTAMP:20260525T062316
CREATED:20220816T161557Z
LAST-MODIFIED:20220816T161557Z
UID:3021-1664447400-1664469000@www.ctnnortheastnode.org
SUMMARY:“Target Trial Emulation in Observational Research and Translational Testing of Advanced Digital Health Tools for SUD Prevention and Treatment" Virtual Workshop
DESCRIPTION:REGISTER HERE! \nDescription: \nObservational research and digital health studies have made significant progress in recent years\, including target trial emulations using real-world data (RWD) and translational testing of digital health tools in real-world settings. This workshop aims to introduce these trending approaches; assess their strengths\, limitations\, and potential; discuss feasible research questions; identify study priorities\, and explore actionable strategies to address barriers and challenges for advancing substance use disorder (SUD) research. \nOnce registered you will receive the Zoom information including an option to download a calendar invitation. \nIf you have any questions about the meeting logistics\, please contact CTNSupport@leedmci.com. If you have any questions about this event\, please contact Dr. Xiaoming Wang at xiaoming.wang@nih.gov. \nIndividuals with disabilities who need sign language interpreting and/or other reasonable accommodations to participate in this event\, should contact Sean Randol at (240) 863-0507 or srandol@leedmci.com or through the Federal Relay (1-800-877-8339). Requests should be made at least five business days in advance of the event. \n 
URL:https://www.ctnnortheastnode.org/event/target-trial-emulation-in-observational-research-and-translational-testing-of-advanced-digital-health-tools-for-sud-prevention-and-treatment-virtual-workshop/
CATEGORIES:Clinical Trials Network
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220906T110000
DTEND;TZID=America/New_York:20220906T170000
DTSTAMP:20260525T062316
CREATED:20220811T183308Z
LAST-MODIFIED:20220811T183308Z
UID:3011-1662462000-1662483600@www.ctnnortheastnode.org
SUMMARY:"Prehospital Treatment for Opioid Use Disorder" Virtual Workshop
DESCRIPTION:REGISTER HERE! \nDescription: \nThe NIDA CCTN is convening stakeholders\, experts\, and federal staff to present recent research and innovative EMS or paramedic administered approaches for opioid use disorder and overdose and to identify research needed to evaluate prehospital approaches for opioid use disorder. The meeting will highlight promising research\, describe innovative programs in the United States\, and identify research priorities to inform research planning. \nOnce registered you will receive the Zoom information including an option to download a calendar invitation. \nIf you have any questions about the meeting logistics\, please contact CTNSupport@leedmci.com. If you have any questions about this event\, please contact Dr. Kristen Huntley at kristen.huntley@nih.gov. \nIndividuals with disabilities who need sign language interpreting and/or other reasonable accommodations to participate in this event\, should contact Sean Randol at (240) 863-0507 or srandol@leedmci.com or through the Federal Relay (1-800-877-8339). Requests should be made at least five business days in advance of the event.
URL:https://www.ctnnortheastnode.org/event/prehospital-treatment-for-opioid-use-disorder-virtual-workshop-2/
CATEGORIES:Clinical Trials Network
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220606T120000
DTEND;TZID=America/New_York:20220606T133000
DTSTAMP:20260525T062316
CREATED:20220527T142254Z
LAST-MODIFIED:20220527T142254Z
UID:2903-1654516800-1654522200@www.ctnnortheastnode.org
SUMMARY:Electronic Informed Consent Guidance: Regulatory Updates
DESCRIPTION:Conducting the informed consent process is one of the most critical tasks to be completed by a research site. It’s essential that a subject clearly understands the information and language in the consent form and that their rights\, safety\, and welfare are not jeopardized. This web seminar will review the essential language in the informed consent document through review of the FDA regulations and guidance documents\, including the December 2016 final guidance\, “Use of Electronic Informed Consent in Clinical Investigations: Questions and Answers.” Additionally\, there will be discussion of some of the challenges faced in consenting pediatric subjects in trials of greater than minimal risk\, the use of translators\, and review of the use of electronic informed consent and electronic signatures. \nParticipation in these training courses are offered on a first-come-first-serve basis. Depending on the level of responses\, there may be limited availability. \nWant to attend this training session in real time? REGISTER HERE to attend the live session. Deadline for live course registration is June 3rd\, 2022. \nNot able to make this date? CLICK HERE to register to view a recorded session. \n 
URL:https://www.ctnnortheastnode.org/event/electronic-informed-consent-guidance-regulatory-updates/
CATEGORIES:Clinical Trials Network
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210304T130000
DTEND;TZID=America/New_York:20210304T170000
DTSTAMP:20260525T062316
CREATED:20210301T180219Z
LAST-MODIFIED:20210301T180219Z
UID:2481-1614862800-1614877200@www.ctnnortheastnode.org
SUMMARY:Reducing Disparities in SUD treatment among African Americans: A way forward for CTN Research - Day Two
DESCRIPTION:CTN Virtual Workshop organized by the Minority Interest Group. \nPrior research found that African Americans (AAs): a) enter treatment later in the course of their addiction trajectory\, b) are more likely to drop out of treatment\, and c) have poorer treatment outcomes than non-Hispanic Whites. \nThis workshop will provide a) an overview of SUD treatments and outcomes for AAs\, b) existing treatment research that might represent opportunities for addressing treatment disparities\, c) ongoing efforts in delivering SUD treatment\, including digital technologies\, in Black communities\, and d) effective targets for adaptations and/or implementation research that could improve SUD treatment outcomes for AAs. The objective of this workshop is to identify potential studies that could be conducted in the CTN. \nRegistration: Zoom Registration Link (connection information will be sent in registration confirmation email) \n \n 
URL:https://www.ctnnortheastnode.org/event/reducing-disparities-in-sud-treatment-among-african-americans-a-way-forward-for-ctn-research-day-two/
CATEGORIES:Clinical Trials Network
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210303T130000
DTEND;TZID=America/New_York:20210303T170000
DTSTAMP:20260525T062316
CREATED:20210301T175856Z
LAST-MODIFIED:20210301T175856Z
UID:2479-1614776400-1614790800@www.ctnnortheastnode.org
SUMMARY:Reducing Disparities in SUD treatment among African Americans: A way forward for CTN Research - Day One
DESCRIPTION:CTN Virtual Workshop organized by the Minority Interest Group. \nPrior research found that African Americans (AAs): a) enter treatment later in the course of their addiction trajectory\, b) are more likely to drop out of treatment\, and c) have poorer treatment outcomes than non-Hispanic Whites. \nThis workshop will provide a) an overview of SUD treatments and outcomes for AAs\, b) existing treatment research that might represent opportunities for addressing treatment disparities\, c) ongoing efforts in delivering SUD treatment\, including digital technologies\, in Black communities\, and d) effective targets for adaptations and/or implementation research that could improve SUD treatment outcomes for AAs. The objective of this workshop is to identify potential studies that could be conducted in the CTN. \nRegistration: Zoom Registration Link (connection information will be sent in registration confirmation email) \n \n  \n  \n 
URL:https://www.ctnnortheastnode.org/event/reducing-disparities-in-sud-treatment-among-african-americans-a-way-forward-for-ctn-research-day-one/
CATEGORIES:Clinical Trials Network
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200724T110000
DTEND;TZID=America/New_York:20200724T120000
DTSTAMP:20260525T062316
CREATED:20200714T135648Z
LAST-MODIFIED:20200714T135648Z
UID:1930-1595588400-1595592000@www.ctnnortheastnode.org
SUMMARY:Guiding Implementation Fidelity to Improve Adoption of Youth Substance Abuse Prevention Programs
DESCRIPTION:The Stages of Implementation Completion (SIC) is an 8-staged measure of implementation process and milestones. Data collected using the SIC has generated a large repository of both successful and non-successful real-world implementation efforts\, allowing for robust analyses and generation of models for paths for implementation success. These models currently are being used to inform a randomized clinical trial evaluating the benefit of adding audit-and-feedback to inform purveyor-site interactions in the real-world adoption of evidence-based youth substance abuse prevention programs. \nPresenter information: \nLisa Saldana\, PhD\nSenior Scientist\nOregon Social Learning Center \nDr. Saldana is an implementation scientist and intervention developer. Her research emphasizes the development of implementation tools and strategies to measure and facilitate implementation of evidence-based practice in real-world settings. Her intervention research has focused on the development of evidence-based programs for the treatment of parental substance abuse in the child welfare system. \nZoom connection information:\nPhone: US: +1 646 558 8656 or +1 669 900 6833\nClick to join Zoom Meeting\nMeeting ID: 552 573 565
URL:https://www.ctnnortheastnode.org/event/guiding-implementation-fidelity-to-improve-adoption-of-youth-substance-abuse-prevention-programs/
CATEGORIES:Clinical Trials Network
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190116T140000
DTEND;TZID=America/New_York:20190116T150000
DTSTAMP:20260525T062316
CREATED:20190109T145800Z
LAST-MODIFIED:20190109T150023Z
UID:1174-1547647200-1547650800@www.ctnnortheastnode.org
SUMMARY:CTN Webinar: Utilizing a Robust and Comprehensive Locator Form as a Retention Tool in Clinical Trials
DESCRIPTION:Phoebe Gauthier\, MA\, MPH from the Northeast Node and Dagmar Salazar\, MS from NDAT CTN Clinical Coordinating Center will present on “Utilizing a Robust and Comprehensive Locator Form as a Retention Tool in Clinical Trials” on January 16th. \nParticipant recruitment and retention are critical aspects of conducting quality clinical research projects. The National Drug Abuse Treatment Clinical Trials Network (NDAT CTN)\, which evaluates behavioral\, pharmacological\, and integrated treatment interventions for substance use disorders\, routinely enrolls participants who may be challenging to locate during the treatment and follow-up phase of a trial. This 20-minute presentation will review one tool for increasing retention—an adapted locator form. This locator form is designed to better facilitate locating participants\, especially those with unstable living conditions or with limited contact information. Additionally\, this presentation will discuss the form elements beyond conventional locator forms and methods for collecting the information to help increase participant retention. \nLEARNING OBJECTIVES: \n· Outline the elements of a comprehensive and robust locator form.\n· Analyze procedural implications for effective implementation of the locator form.\n· Review best practices when collecting contact information with the locator form. \nThey will also be joined by presenters from the Ohio Valley Node whose theme will also focus on study participant retention strategies and tools. \nRegister here: https://cc.readytalk.com/registration/#/?meeting=oc60vlwip9eu&campaign=gi7gdsjt78ri
URL:https://www.ctnnortheastnode.org/event/ctn-webinar-utilizing-robust-comprehensive-locator-form-retention-tool-clinical-trials/
LOCATION:Web Based
CATEGORIES:Clinical Trials Network,Northeast Node
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190109T140000
DTEND;TZID=America/New_York:20190109T150000
DTSTAMP:20260525T062316
CREATED:20181217T182115Z
LAST-MODIFIED:20181217T182115Z
UID:1132-1547042400-1547046000@www.ctnnortheastnode.org
SUMMARY:DSC Manual Query Training
DESCRIPTION:The NDAT CTN Data and Statistics Center (DSC) at The Emmes Corporation will soon implement a new feature in Advantage eClinical–the Manual Query feature. \n\nThe new feature will allow data management staff to highlight data fields that require additional clarification or action by research site staff.\nThis new feature will be used in addition to the Data Integrity queries.\n\nThe DSC will provide training and a demonstration on the functionality of the manual query feature to CTN researchers on Wednesday\, January 9\, 2019. \nWHO SHOULD ATTEND? \nAll CTN node and research site staff who have Read/Write access to Advantage eClinical and enter data into the system are required to attend this training. If you are not able to attend this session\, you may review the recording once it is available.
URL:https://www.ctnnortheastnode.org/event/dsc-manual-query-training/
CATEGORIES:Clinical Trials Network
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20180213T140000
DTEND;TZID=America/New_York:20180213T150000
DTSTAMP:20260525T062316
CREATED:20180122T185020Z
LAST-MODIFIED:20180206T165739Z
UID:646-1518530400-1518534000@www.ctnnortheastnode.org
SUMMARY:Appropriate Opioid Prescribing for Acute Pain after Surgery\, Dr. Richard Barth Jr.
DESCRIPTION:During this webinar\, Dr. Barth\, Chief of General Surgery at Dartmouth-Hitchcock Medical Center\, will discuss 3 recent papers that evaluated opioid prescribing after outpatient and inpatient general surgical operations. Briefly\, the papers reported on:\n· the evaluation of variation in opioid prescribing\, how much of prescribed opioids were used (over prescription)\, and proposed prescribing guidelines;\n· the results of educating surgeons about the findings from the first paper and the observed decrease in opioid prescribing; and\n· the evaluation of opioid prescribing and use after inpatient operations; which showed that home use was best predicted by the number of pills taken the day prior to discharge.
URL:https://www.ctnnortheastnode.org/event/ctn-steering-committee-presentation-dr-richard-barth/
LOCATION:Web-Based
CATEGORIES:Clinical Trials Network
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20171002T120000
DTEND;TZID=America/New_York:20171002T133000
DTSTAMP:20260525T062316
CREATED:20170913T154650Z
LAST-MODIFIED:20170913T154650Z
UID:594-1506945600-1506951000@www.ctnnortheastnode.org
SUMMARY:CSAT/CTN Webinar: Digital Therapeutics for Substance Use Disorders
DESCRIPTION:“Digital Therapeutics for Substance Use Disorders: The State of the Science and Opportunities for Implementation in Substance Use Disorder Care” \nThis webinar is the fourth in a series of collaborative webinars between the CTN and CSAT. In this webinar\, an overview of the state of the science of applying digital therapeutics (e.g.\, mobile\, web-based therapeutic tools) to substance use disorder (SUD) care will be presented (30 minutes). CSAT will provide an overview of their portfolio on the intersection of digital technology and SUDs\, and CSAT grantees will provide a few examples of this work (30 minutes). The presentations will be followed by a 30 minute discussion with meeting participants on challenges and opportunities in sustainable implementation of digital therapeutics in SUD care. \nJoin the webinar here (type your name and select “Enter Room”)\nPlease dial into the audio portion of the webinar:\nDial in: 1-877-226-9607\nEnter Passcode: 9260084283#
URL:https://www.ctnnortheastnode.org/event/csatctn-webinar-digital-therapeutics-substance-use-disorders/
CATEGORIES:Clinical Trials Network
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20170920T130000
DTEND;TZID=America/New_York:20170920T140000
DTSTAMP:20260525T062316
CREATED:20170913T153342Z
LAST-MODIFIED:20170913T154740Z
UID:593-1505912400-1505916000@www.ctnnortheastnode.org
SUMMARY:CTN Webinar: Testing Chronic Care Models for  Tobacco Use Disorder
DESCRIPTION:The CTN Web Seminar Series presents: Anne Joseph\, MD\, MPH. \nTreatment of tobacco use disorder is challenging\, and many smokers require multiple quit attempts before they achieve long term abstinence. Nevertheless\, typical treatment is based on a discrete model of care lasting 8-12 weeks\, with little attention to how or if treatment should be modified in subsequent quit attempts. This presentation will describe two randomized clinical trials for smoking cessation. The Tobacco Longitudinal Care (TLC) study showed that a chronic care model significantly improved long-term quit rates compared to usual care. The Program for Lung Cancer Screening and Tobacco Treatment (PLUTO) is a sequential multiple assignment randomized trial (SMART) that includes three potential randomizations for current smokers who are undergoing lung cancer screening with low dose CT scanning. \nLEARNING OBJECTIVES \n\nDiscuss the relevance of longitudinal care treatment interventions for substance use treatment.\nReview the strengths and weaknesses of a sequential multiple assignment randomized trial (SMART) for substance use treatment interventions.\nConsider the challenges of implementing a chronic care treatment model for substance use treatment.\nEvaluate the relevance of the tobacco use disorder example to investigations of marijuana\, opiates\, or other drug treatment.\n\nClick here to register
URL:https://www.ctnnortheastnode.org/event/ctn-webinar-testing-chronic-care-models-tobacco-use-disorder/
CATEGORIES:Clinical Trials Network
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20170427T130000
DTEND;TZID=America/New_York:20170427T140000
DTSTAMP:20260525T062316
CREATED:20170421T204958Z
LAST-MODIFIED:20170421T205025Z
UID:475-1493298000-1493301600@www.ctnnortheastnode.org
SUMMARY:CTN Webinar: Potential Benefits of Increased Use of Prescription Monitoring Programs
DESCRIPTION:National Drug Abuse Treatment Clinical Trials Network Webinar titled Potential Benefits of Increased Use of Prescription Monitoring Programs presented by Dr. Thomas Alfieri on Thursday\, April 27\, 2017 from 1:00 – 2:00 PM EDT.  \nEvent Description: \nPurdue Pharma L.P.\, Virginia Governor Terry McAuliffe and the Virginia Secretary of Health and Human Resources announced the formation of a public-private partnership to enhance utilization of the state prescription monitoring program (PMP) as part of the solution to address the opioid crisis. The Commonwealth of Virginia will connect the state PMP to the electronic health records (EHR) used by Virginia prescribers and pharmacists to make information from the PMP an integral part of the patient workflow when prescribing or dispensing controlled substances. The goal is to improve the performance\, access and usability of the PMP program data for 18\,000 prescribers and 400 pharmacies in the Commonwealth of Virginia by the end of 2017. \nThe Virginia PMP provides to authorized users a patient’s prescription history for Schedule II – V prescriptions for the prior 12 months as reported by all Virginia pharmacies and by out-of-state pharmacies delivering to people in Virginia. Additionally\, the PMP prescription report informs clinical decision-making to help prevent or stop harm from duplicate drug therapy\, prescription drug misuse\, abuse and diversion. \nThis presentation will outline the potential benefits of PMP use\, and explore ways that these benefits can be measured. \n  \nPresenter Information: \nThomas Alfieri\, PhD\, is a director of strategic research at Purdue Pharma L.P.\, where he is responsible for developing and executing a program of collaborative research partnerships aimed at improving pain management and decreasing opioid misuse. Current research projects include examining the role of prescription monitoring programs in preventing opioid misuse\, the impact of medicine disposal initiatives on public health\, and the effect of wearable health technologies on patient outcomes among chronic pain patients.  He earned his doctorate in social psychology from New York University and advanced degrees in statistics and operations research from NYU’s Stern School of Business. Dr. Alfieri has spent the majority of his professional career designing research projects in a variety of fields including health outcomes\, consumer perception\, and marketing.  \nFor information on how to register\, please contact the Northeast Node.
URL:https://www.ctnnortheastnode.org/event/ctn-webinar-potential-benefits-increased-use-prescription-monitoring-programs/
CATEGORIES:Clinical Trials Network
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20170322T080000
DTEND;TZID=America/New_York:20170324T170000
DTSTAMP:20260525T062316
CREATED:20161214T182332Z
LAST-MODIFIED:20161214T182412Z
UID:407-1490169600-1490374800@www.ctnnortheastnode.org
SUMMARY:Clinical Trials Network Annual Scientific Meeting
DESCRIPTION:More information coming soon!
URL:https://www.ctnnortheastnode.org/event/clinical-trials-network-annual-science-meeting/
CATEGORIES:Clinical Trials Network
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20161130T130000
DTEND;TZID=America/New_York:20161130T140000
DTSTAMP:20260525T062316
CREATED:20160405T163427Z
LAST-MODIFIED:20160405T163427Z
UID:298-1480510800-1480514400@www.ctnnortheastnode.org
SUMMARY:CTN Web Seminar Series: Perceptions of Harm and Addiction of SNUS
DESCRIPTION:SEMINAR DESCRIPTION\nChanges in public attitudes toward smoking have led to reductions in cigarette consumption in the United States. Tobacco companies in the United States are prohibited from making reduced harm claims without filing a modified risk tobacco product application with the Food and Drug Administration and obtaining an order to market as such. However\, product marketing may suggest reduced risk to individuals. This study examines perceptions\, in particular those related to harm and addiction\, of snus print advertisements. A mixed-methods design combined eye-tracking\, survey\, and semi-structured interviews. Results from the study may provide a better understanding of how smokers perceive and understand products after viewing advertisements\, which may guide public health efforts to educate smokers on the risks of emerging products. \n  \nLEARNING OBJECTIVES\n\nReview information about tobacco regulation in the U.S.\, current and historical trends in tobacco use in the U.S.\, harm perceptions\, and health outcomes associated with tobacco use.\nDiscuss the purpose\, design\, and methods of a mixed methods study examining how print advertising may influence perceptions about snus.\nReport study outcomes and future directions.\n\n  \nTARGET AUDIENCE\nEveryone is welcome! \n  \nAbout the Presenter\nAnnette Kaufman\, PhD\nDr. Kaufman is a Health Scientist and Program Director in the Tobacco Control Research Branch (TCRB)\, Behavioral Research Program (BRP)\, Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute (NCI). She obtained her Doctorate in Applied Social Psychology from The George Washington University and Master of Public Health in quantitative methods from the Harvard School of Public Health. She completed her post-doctoral training as a Cancer Prevention Fellow in the Office of the Director (OAD) in the Behavioral Research Program. Dr. Kaufman is actively involved in the development and implementation of the Health Information National Trends Survey (HINTS) and the Population Assessment of Tobacco and Health (PATH) study. Her program of research focuses on tobacco product harm judgments and risk perceptions associated with tobacco use. Dr. Kaufman is particularly interested in the influence of policy on tobacco beliefs and behavior.
URL:https://www.ctnnortheastnode.org/event/ctn-web-seminar-series-perceptions-harm-addiction-snus/
CATEGORIES:Clinical Trials Network
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20161019T130000
DTEND;TZID=America/New_York:20161019T140000
DTSTAMP:20260525T062316
CREATED:20160405T163017Z
LAST-MODIFIED:20160412T184741Z
UID:297-1476882000-1476885600@www.ctnnortheastnode.org
SUMMARY:CTN Web Seminar Series: Preparation for drug management and accountability in a CTN clinical trial
DESCRIPTION:SEMINAR DESCRIPTION\nIn preparation for the conduct of a clinical trial\, investigators must plan for the management of medications used as an intervention or a supportive drug. In setting up for a study\, there are various aspects to consider for implementation\, tracking\, and quality assurance. This one-hour seminar will discuss drug management planning and implementation considerations for trials in the CTN. \n  \nLEARNING OBJECTIVES\n\nDescribe drug management planning and preparation activities.\nDiscuss tools for drug inventory and drug accountability tracking.\nDefine implementation challenges and quality assurance.\n\n  \nTARGET AUDIENCE\nEveryone is welcome! This session is targeted to research staff with responsibilities for drug management planning and implementation in clinical trials. \n  \nAbout the Presenters\nPatricia Novo\, MPA\, MPH\nPatricia “Patsy” Novo is an Assistant Research Scientist in the Department of Psychiatry at NYU’s School of Medicine where she is responsible for project planning and resource allocation for clinical trials in mental health and addiction. Patsy has been part of the CTN since its earliest days and is currently the National Project Manager for the CTN-0051 study. Prior to joining the staff at NYU\, she provided technical assistance to non-profit organizations\, planned projects to improve women’s health in developing countries\, and was part of the founding team of Action Without Borders/idealist.org\, among other work activities. Patsy has a BS degree from Cornell University\, an MPA in Management from the Wagner School of Public Service at NYU\, and a Master’s degree in Global Public Health from NYU. \nBeth Jeffries\, BS\, CCRP \nBeth Jeffries is a Protocol Monitor for the National Drug Abuse Treatment Clinical Trials Network (NDAT CTN) Clinical Coordinating Center at The Emmes Corporation. Since 2008\, she has been providing Quality Assurance (QA) support on numerous CTN drug and non-drug studies\, with responsibilities for monitoring and reporting\, providing guidance and training to site staff on protocol adherence\, regulatory\, safety\, and other site/study specific concerns as well as providing study set-up and implementation support services. Previously\, Beth worked as a clinical research associate\, research program coordinator\, and laboratory technician with the National Cancer Institute and other research organizations. Beth obtained a BS degree in Biology from Bennett College\, and she is CCRP certified by the Society of Clinical Research Associates (SOCRA).
URL:https://www.ctnnortheastnode.org/event/ctn-web-seminar-series-preparation-drug-management-accountability-ctn-clinical-trial/
CATEGORIES:Clinical Trials Network
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20160914T130000
DTEND;TZID=America/New_York:20160914T140000
DTSTAMP:20260525T062316
CREATED:20160405T162150Z
LAST-MODIFIED:20160405T163149Z
UID:296-1473858000-1473861600@www.ctnnortheastnode.org
SUMMARY:CTN Web Seminar Series: Demonstrating Practical Use of Data Share and secondary analyses
DESCRIPTION:SEMINAR DESCRIPTION\nThe NIDA Data Share website was created to make CTN data available to the scientific community and the public at large. These data can be used for secondary analyses and thus serve to increase the contribution of the original studies conducted and extend findings into new areas and knowledge for the benefit of public health. This one-hour presentation will focus on an overview of the website\, provide highlights of its structure and contents\, and detail the technical procedures involved in utilizing the data for secondary analyses. \n  \nLEARNING OBJECTIVES\n\nReview the structure of the NIDA Data Share website.\nUnderstand the information provided\, how to navigate through the website\, and obtain all the relevant information.\nDemonstrate the technical procedures for using SAS or ASCII data sets for conducting secondary analyses.\n\n  \nTARGET AUDIENCE:\nEveryone is welcome! This webinar is targeted to all research professionals responsible for the development of research trials and those interested in secondary analyses and expanding their use of CTN trial data sets. \n  \nAbout the Presenter\nAbigail Matthews\, PhD\nDr. Matthews joined The Emmes Corporation in January 2010 and provides statistical support for several projects\, including the National Drug Abuse Treatment Clinical Trials Network (NDAT CTN). As a post- doctoral associate at the University of Pittsburgh\, she began research in the genetics of alcohol dependence and engaged in analyses of psychological characteristics in childhood predicting future alcohol abuse and dependence. At Rockefeller University\, Dr. Matthews collaborated with researchers at a major pharmaceutical company where she performed pharmacogenomic analyses to predict which subjects would respond to a particular drug and identify subjects at higher risk of side effects due to that medication. She also has experience working with registry data as a research assistant consulting with the Cancer Genetics Network. \nDikla Blumberg\, PhD\nDr. Blumberg is the Project Manager for the National Drug Abuse Treatment Clinical Trials Network (NDAT CTN) Clinical Coordinating Center at The Emmes Corporation. She is a Social Psychologist with expertise in self-regulation processes and over 10 years of experience in behavioral research. Previously\, Dr. Blumberg worked in a NIDAfunded Postdoctoral Traineeship in Drug Abuse Treatment and Services Research at UCSF\, where she designed and implemented a series of experiments investigating self-regulation processes involved with tobacco dependence. Additionally\, she worked on a Cancer Research Training Award at the National Cancer Institute’s Behavioral Research Program\, where she was involved with projects designed to better understand health behaviors and their underlying processes.
URL:https://www.ctnnortheastnode.org/event/ctn-web-seminar-series-demonstrating-practical-use-data-share-secondary-analyses/
CATEGORIES:Clinical Trials Network
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20160810T130000
DTEND;TZID=America/New_York:20160810T140000
DTSTAMP:20260525T062316
CREATED:20160405T161749Z
LAST-MODIFIED:20160405T163507Z
UID:295-1470834000-1470837600@www.ctnnortheastnode.org
SUMMARY:CTN Web Seminar Series: Pharmacotherapy trials for adolescent substance use disorders: From concept to execution
DESCRIPTION:SEMINAR DESCRIPTION\nWhile several pharmacotherapies have been developed for substance use disorders (SUD) in adults\, relatively few have been studied in adolescents\, and complex design and execution issues must be addressed to optimize the potential impact of current and future research in this important area. This one-hour presentation will discuss method\, design\, and key strategies for the optimization of conduct/execution\, overall treatment adherence\, participant enrollment and retention\, documentation\, and management of adverse events for adolescent SUD pharmacotherapy trials. With adequate understanding of challenges and opportunities in the design and conduct of these trials\, attendees will be equipped to incorporate this information into their research practices. \n  \nLEARNING OBJECTIVES\n\nIdentify key issues in the conceptualization/design of pharmacotherapy trials for adolescent substance use disorders (SUD).\nUnderstand methods to optimize the management/execution of pharmacotherapy trials for adolescent SUD.\nConsider strategies to standardize design methods across adolescent SUD pharmacotherapy trials.\n\n  \nTARGET AUDIENCE\nEveryone is welcome! This webinar is targeted to all investigators\, clinicians\, statisticians\, and research staff engaged in the planning and development of pharmacotherapy trials. \n  \nAbout the Presenter\nKevin M. Gray\, MD\nDr. Gray is Professor and Director of Child and Adolescent Psychiatry at the Medical University of South Carolina in Charleston\, South Carolina. Dr. Gray maintains active clinical practice and conducts National Institutes of Health sponsored clinical research on substance use disorders in adolescents and young adults\, with particular emphasis on treatment development for cannabis and tobacco use disorders in youth. With a multidisciplinary group of collaborators\, Dr. Gray investigates biobehavioral mechanisms underlying substance use disorders\, and works to apply these findings to real world clinical practice.
URL:https://www.ctnnortheastnode.org/event/ctn-web-seminar-series-pharmacotherapy-trials-adolescent-substance-use-disorders-concept-execution/
CATEGORIES:Clinical Trials Network
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20160713T130000
DTEND;TZID=America/New_York:20160713T140000
DTSTAMP:20260525T062316
CREATED:20160405T161426Z
LAST-MODIFIED:20160405T163539Z
UID:293-1468414800-1468418400@www.ctnnortheastnode.org
SUMMARY:CTN Web Seminar Series: In the Weeds: Assessing neurocognitive brain imaging and substance abuse measures in emerging adults
DESCRIPTION:SEMINAR DESCRIPTION\nMultimodal studies which combine cognitive\, clinical\, neuroimaging and substance use assessments are critical to understanding the impact of substance use in emerging adults. These can be difficult\, however\, and a number of important yet confounding factors often cloud data collection. The goals of this one-\nhour presentation are to: 1) review the importance of collecting accurate and comprehensive information; 2) acknowledge the most common confounding variables; and 3) provide strategies for improving data collection among this population. These will be presented in conjunction with data and methodologic examples from ongoing NIDA and other funded studies. \n  \nLEARNING OBJECTIVES\n\nDefine some of the difficulties associated with assessing substance use in adolescent and emerging adult populations. • Recognize the importance of a clear study design with well-articulated substance use assessment measures administered in a reliable\, consistent\, and comprehensive manner.\nUnderstand how to modify common tools for substance use assessment for a range of substances (i.e.\, TLFB).\nIdentify a number of ways to improve the quality of data/information offered by adolescent/emerging adult research participants.\n\n  \nTARGET AUDIENCE\nEveryone is welcome to attend! \n  \nAbout the Presenter\nDr. Staci Gruber.\, PhD\nDr. Staci Bruber is the Director of the Cognitive and Clinical Neuroimaging Core at McLean Hospital’s Brain Imaging Center and an Associate Professor of Psychiatry at Harvard Medical School. Dr. Gruber’s clinical and research focus is the application of neurocognitive models and multimodal brain imaging to better characterize neurobiological risk factors for substance abuse and psychopathology\, particularly disruptions of the frontal network. In recent work\, her lab has examined the etiologic bases of neural models of dysfunction in patients with bipolar disorder as well as marijuana-\nusing adolescents and adults\, the results of which have been published in numerous peer reviewed journals and been the basis of national and international symposia\, documentaries and press conferences. Dr. Gruber has also been involved in the application of behavioral science to help shape policies regarding juvenile advocacy and defense; her lab’s work in adolescent development was part of the Amicus brief leading to the Supreme Court’s landmark decision in Roper vs. Simmons\, which states that it is unconstitutional to execute minors. Her ongoing initiative to educate policymakers\, judges\, attorneys and the general public in the differences between adults and adolescents and the impact of marijuana on the brain has already had both local and national impact on policy formation. She also directs the newly launched MIND (Marijuana Investigations for Neuroscientific Discovery) Program\, designed to clarify the effects of medical marijuana on brain structure\, function\, and quality of life.
URL:https://www.ctnnortheastnode.org/event/ctn-web-seminar-series-weeds-assessing-neurocognitive-brain-imaging-substance-abuse-measures-emerging-adults/
CATEGORIES:Clinical Trials Network
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20160525T010000
DTEND;TZID=America/New_York:20160525T020000
DTSTAMP:20260525T062316
CREATED:20160405T161037Z
LAST-MODIFIED:20160412T181955Z
UID:292-1464138000-1464141600@www.ctnnortheastnode.org
SUMMARY:CTN Web Seminar Series: CTN-0044 WEB-TX
DESCRIPTION:DESCRIPTION\nThe National Drug Abuse Treatment Clinical Trials Network WEB-TX study is one of the largest randomized controlled trials to date examining the effectiveness of an internet-delivered treatment intervention on clinical outcomes among people receiving outpatient substance abuse treatment. In addition to the primary outcome analysis showing significant improvements in abstinence and treatment retention among people randomized to the internet-delivered treatment arm\, the study has produced three methodological publications\, four baseline publications\, five secondary outcome publications\, and an additional seven secondary outcome publications under review or in preparation. The purpose of this one-hour webinar is to present a synthesis of WEB-TX study findings\, focusing on key secondary clinical outcomes\, and discuss new areas of research for technology-based treatments for substance use disorders. \n  \nLEARNING OBJECTIVES\n\nUnderstand the design and methodological decisions critical to the implementation of an effectiveness trial of a technology-based intervention.\nReview the primary outcomes and key secondary outcomes of the WEB-TX study.\nDiscuss new areas of research for technology-based interventions.\n\n  \nTARGET AUDIENCE\nEveryone is welcome! This webinar is targeted to investigators\, research staff\, and community providers interested in technology-based interventions for substance use disorders. \n  \nAbout the Presenters\nEdward V. Nunes Jr.\, MD\nDr. Nunes is a Professor of Psychiatry and Principal Investigator of the Greater New York Node of the National Institute on Drug Abuse (NIDA) Clinical Trials Network as well as other NIDA funded studies on behavioral and medication treatments for substance dependence and related psychiatric disorders. Interests and ongoing studies include treatments for cocaine dependence in general\, heroin and other opioid dependence\, for nicotine dependence in general\, and for addicted patients with co-occurring psychiatric disorders including depression\, and post-traumatic stress disorder. Types of treatment under study include medication treatments (naltrexone\, buprenorphine\, mirtazapine) as well as behavioral and psychotherapeutic approaches and computer-delivered treatments. Dr. Nunes also studies the challenges involved in implementing evidence-based treatments for substance use disorders in real-world community-based treatment settings. Dr. Nunes also serves on the American Board of Addiction Medicine\, Co-Chair of the Columbia/New York State Psychiatric Institute’s Institutional Review Board\, and has been appointed to the National Advisory Council on Drug Abuse. \nAimee Campebll\, PhD \nAimee Campbell\, PhD\, is a Research Scientist in the Substance Abuse Division of the New York State Psychiatric Institute (NYSPI) and an Assistant Professor of Clinical Psychiatric Social Work in the Department of Psychiatry at the Columbia University Medical Center. She was the Project Director for the NIDA Clinical Trials Network 0044 study. Her research interests center on the development and testing of behavioral interventions for substance use disorders and HIV prevention and treatment\, including through use of technology-based platforms\, with a specific emphasis on methods to improve access to and implementation of science-based treatments. Dr. Campbell’s work incorporates the personal\, interpersonal\, and social contexts in which individuals manage the overlapping challenges of addiction\, trauma\, mental health disorders\, and HIV sexual and drug risk behaviors. She has extensive experience in the development\, implementation\, and oversight of large community-based clinical trials. She has been involved in treatment research for substance use disorders\, primarily in community settings and in partnership with community providers and consumers\, for 20 years. Dr. Campbell completed undergraduate training in sociology at the University of Washington and received her master’s degree and doctorate from Columbia University School of Social Work.
URL:https://www.ctnnortheastnode.org/event/ctn-web-seminar-series-ctn-0044-web-tx-review-primary-secondary-outcomes/
CATEGORIES:Clinical Trials Network
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20160420T130000
DTEND;TZID=America/New_York:20160420T140000
DTSTAMP:20260525T062316
CREATED:20160405T151017Z
LAST-MODIFIED:20160405T163119Z
UID:289-1461157200-1461160800@www.ctnnortheastnode.org
SUMMARY:CTN Web Seminar Series: CTN Investigator Toolbox – An Orientation
DESCRIPTION:Seminar Description\nThe Clinical Trials Network (CTN) Investigator Toolbox is a resource to investigators who are conducting studies within the CTN. The Toolbox provides templates for regulatory and other key study documents (e.g.\, Protocol Template\, Form FDA 1572) and guidance on the tasks and processes associated with developing\, implementing\, and publishing a NIDA CTN clinical research study. This one-hour webinar will be a comprehensive review of the design of the website and resources made available to study investigators. \n  \nLearning Objectives\n\nIdentify the location of the Investigator Toolbox.\nDescribe the sections and some of the main tools and documents within each section of the Toolbox.\nUnderstand the ways in which the Toolbox can be used as a resource for those involved in developing\, implementing\, and managing clinical trials.\n\n  \nTarget Audience\nEveryone is welcome! This training is targeted to Investigators\, Project Directors\, and all research staff engaged in development\, implementation\, and closeout activities for CTN studies and sites. \n  \nAbout the Presenters\nDikla Blumberg\, PhD\nDr. Blumberg is the Project Manager for the National Drug Abuse Treatment Clinical Trials Network (NDAT CTN) Clinical Coordinating Center at The Emmes Corporation. She is a Social Psychologist with expertise in self-regulation processes and over 10 years of experience in behavioral research. Previously\, Dr. Blumberg worked in a NIDAfunded Postdoctoral Traineeship in Drug Abuse Treatment and Services Research at UCSF\, where she designed and implemented a series of experiments investigating self-regulation processes involved with tobacco dependence. Additionally\, she worked on a Cancer Research Training Award at the National Cancer Institute’s Behavioral Research Program\, where she was involved with projects designed to better understand health behaviors and their underlying processes. \nCarmen Rosa\, MS\nMs. Carmen Rosa works at the Center for Clinical Trials Network\, within the National Institute on Drug Abuse (NIDA)\, National Institutes of Health (NIH). She has been with NIDA since 1999\, when NIDA started the National Drug Abuse Treatment Clinical Trials Network (CTN). Since then\, she has held several roles overseeing the Network’s research management and implementation. Currently\, Ms. Rosa serves as Regulatory Officer at the CCTN providing regulatory consultations to investigators and NIDA staff. Her other major responsibilities include working with CTN staff and investigators in developing and implementing clinical trials\, managing Protocol Review and Data and Safety Monitoring Boards that review and oversee various multi- site trials\, coordinating the CTN international activities\, and serving as an advocate for women and minority participation in research.
URL:https://www.ctnnortheastnode.org/event/ctn-web-seminar-series-ctn-investigator-toolbox-orientation/
CATEGORIES:Clinical Trials Network
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160411
DTEND;VALUE=DATE:20160414
DTSTAMP:20260525T062316
CREATED:20160405T150751Z
LAST-MODIFIED:20160405T150751Z
UID:286-1460332800-1460591999@www.ctnnortheastnode.org
SUMMARY:Clinical Trials Network Annual Scientific Meeting
DESCRIPTION:
URL:https://www.ctnnortheastnode.org/event/clinical-trials-network-annual-scientific-meeting/
CATEGORIES:Clinical Trials Network
END:VEVENT
END:VCALENDAR